Publicacións en colaboración con investigadores/as de Pfizer (United States) (8)

2024

  1. Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer

    Clinical Drug Investigation, Vol. 44, Núm. 8, pp. 553-576

2023

  1. Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations

    Journal of Thoracic Oncology, Vol. 18, Núm. 11, pp. 1581-1593

2022

  1. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

    European Journal of Cancer, Vol. 168, pp. 12-24

2021

  1. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

    European Journal of Cancer, Vol. 156, pp. 70-82

  2. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

    The Lancet Oncology, Vol. 22, Núm. 2, pp. 212-222

2019

  1. Development and validation of a sexual relations satisfaction scale in patients with breast cancer - "sEXSAT-Q"

    Health and Quality of Life Outcomes, Vol. 17, Núm. 1

2011

  1. Expression of notch1 to -4 and their ligands in renal cell carcinoma: A tissue microarray study

    Cancer Genomics and Proteomics, Vol. 8, Núm. 2, pp. 93-101

  2. Fructose transporter GLUT5 expression in clear renal cell carcinoma

    Oncology Reports, Vol. 25, Núm. 2, pp. 315-323